ImmuFact IMP321: Interim Phase I/II data

In an open-label, dose-escalation, French Phase I/II trial, initial data from 8 patients receiving 0.25 mg of subcutaneous IMP321 plus paclitaxel showed 6 cases of tumor regression and 1 patient with ...